Costs of Community-Based Viral Hepatitis Screening in Cameroon Using Point-of-Care Technologies-Reference-Cited by-同舟云学术

Costs of Community-Based Viral Hepatitis Screening in Cameroon Using Point-of-Care Technologies

Published:2024-06-28 Issue:7 Volume:11 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Tazinkeng Nkengeh N¹²³^ORCID,Mohareb Amir M⁴⁵⁶,Asombang Akwi W²³⁶,Hyle Emily P⁴⁵⁶^ORCID

Affiliation:

1. Department of Population Health Research, Health Education and Research Organization , Buea , Cameroon

2. Division of Gastroenterology, Massachusetts General Hospital , Boston, Massachusetts , USA

3. Department of Research, Pan-African Organization for Health, Education and Research , Manchester, Missouri , USA

4. Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts , USA

5. Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, Massachusetts , USA

6. Department of Medicine, Harvard Medical School , Boston, Massachusetts , USA

Abstract

Abstract This cost analysis of a community-based viral hepatitis screening program in Cameroon found an investment of $3.52 per person screened, $50.63 per new diagnosis of hepatitis B, $159.45 per new diagnosis of hepatitis C, and $47.97 per new diagnosis of either hepatitis B or C.

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofae378/58408045/ofae378.pdf

Reference16 articles.

1. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis;Nayagam;Lancet Global Health,2016

2. Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, West Africa: a cost-effectiveness analysis;Nguyen;Lancet Global Health,2024

3. Seroprevalence of hepatitis B virus infection in Cameroon: a systematic review and meta-analysis;Bigna;BMJ Open,2017

4. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study;Polaris Observatory Collaborators;Lancet Gastroenterol Hepatol,2018